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Background: Circulating adipocyte fatty acid-binding protein (FABP4) levels are considered to be a link between
obesity, insulin resistance, diabetes, and cardiovascular (CV) diseases. In vitro, FABP4 has exhibited cardiodepressant
activity by suppressing cardiomyocyte contraction. We have explored the relationship between FABP4 and the
N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) as a clinical parameter of heart failure (HF).
Methods: We included 179 stable HF patients who were referred to a specialized HF unit, 108 of whom were
prospectively followed for up to 6 months. A group of 163 non-HF patients attending a CV risk unit was used as
the non-HF control group for the FABP4 comparisons.
Results: In the HF patients, FABP4 and NT-proBNP were assayed, along with a clinical and functional assessment of
the heart at baseline and after 6 months of specialized monitoring. The FABP4 levels were higher in the patients
with HF than in the non-HF high CV risk control group (p<0.001). The FABP4 levels were associated with the
NT-proBNP levels in patients with HF (r=0.601, p<0.001), and this association was stronger in the diabetic patients.
FABP4 was also associated with heart rate and the results of the 6-minute walk test. After the follow-up period,
FABP4 decreased in parallel to NT-proBNP and to the clinical parameters of HF.
Conclusions: FABP4 is associated with the clinical manifestations and biomarkers of HF. It exhibits a parallel
evolution with the circulating levels of NT-proBNP in HF patients.
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Heart failure (HF) is increasing worldwide, with an over-
all estimated prevalence of 4% and a prevalence of more
than 10% in people older than seventy [1]. Overweight
and obese patients have an increased risk of developing
HF, and metabolic alterations that are strongly related to
adiposity, such as metabolic syndrome (MS) and type-2
diabetes, are also associated with an increased risk of
HF [2]. The main cardiac disease associated with these
metabolic disorders is coronary artery disease, which can
lead to HF. However, in obese, MS and type-2 diabetic
patients, HF also appears independently of vascular
lesions after years of the development of sub-clinical
left systolic dysfunction [3]. Diabetic patients are at a
two- to five-fold increased risk of HF [4], whereas the* Correspondence: luis masana@urv.cat
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reproduction in any medium, provided the orattributed risk of HF due to obesity is 14% in women
and 8.8% in men, and the risk of incident HF in adults
with a body mass index (BMI) > 30 is 1% per year for
men and 0.7% per year for women [3]. However, some
studies suggest that obesity per se could play a parado-
xical beneficial role in HF [5]. The mechanisms leading
to cardiac dysfunction in both obesity and diabetes have
been intensively investigated, and although several hy-
potheses have been raised, the basic etiology remains
speculative. Among the molecules released in excess by
the adipose tissue of obese, MS and diabetic patients is
adipocyte fatty acid-binding protein (FABP4). FABP4 is a
small cytoplasmic lipid chaperone that plays an import-
ant role in the trafficking of fatty acids in subcellular
compartments [6]. In animal models, a FABP4 deficiency
has been linked to reduced lipolysis and inflammation,
as well as protection from the development of hyperin-
sulinemia, hyperglycemia, insulin resistance, and athero-
sclerosis [7-9]. FABP4 is highly expressed in adiposetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phages. FABP4 expression in macrophages plays a speci-
fic and independent role in experimental atherosclerosis.
In humans, FABP4 has been detected in circulation and
seems to be a marker of adiposity and body fat distribu-
tion [10]. FABP4 levels are increased in overweight and
obese subjects compared with those in lean subjects,
and several pathologies have been linked to adipose
tissue dysfunction, such as MS, type-2 diabetes, athero-
genic dyslipidemia, human immunodeficiency-virus as-
sociated lipodystrophy, and polycystic ovary syndrome
[10-14]. Serum FABP4 levels have been shown to predict
the risk of developing both type-2 diabetes and MS
[15,16]. Moreover, serum FABP4 has been associated
with the presence and degree of cardiovascular disease
[17], with an increased risk for secondary cardiovascular
events (particularly cardiovascular death) [18], and also
with renal dysfunction in patients with stable angina
pectoris [19]. Although the function of serum FABP4
has not yet been elucidated, results from recent publica-
tions suggest a systemic effect of FABP4 on peripheral
tissues. In diabetic subjects, elevated FABP4 levels in the
serum have been associated with endothelial dysfunction
[20]. In vitro studies have shown that FABP4 contributes
to endothelial dysfunction [21] and exhibits a cardio-
myocyte depressing action [22]. FABP4 inhibits the cell
shortening amplitude and the intracellular systolic peak
Ca2+ in a dose-dependent manner in isolated rat car-
diomyocytes, most likely due to a reduced excitation-
contraction gain [22]. However, FABP4 is expressed in
endothelial cells and this expression could potentially
contribute to the FABP4 levels observed in patients with
HF. Therefore, this molecule could be considered a
link between obesity, MS, type-2 diabetes, and cardiac
insufficiency.
In this study, we have explored the hypothesis that cir-
culating FABP4 levels are associated with the biomarkers
of HF, such as the N-terminal fragment of pro-B-type
natriuretic peptide (NT-proBNP), and with HF clinical
parameters.
Methods
A case–control and cross-sectional study was performed
using the basal data and a prospective evaluation after a
6-month follow-up period.
Between March, 2006 and July, 2010, 179 patients in
stable HF condition who were referred to a multidiscip-
linary outpatient HF program in the Hospital Universi-
tari de Tarragona Joan XXIII were included. A total of
41.3% of these patients presented ischemic HF, 20.6%
presented idiopathic HF, and 21.2% presented hyperten-
sive HF, whereas 16.7% of the patients presented other
etiologies. The inclusion criteria were a confirmed diag-
nosis of HF based on clinical criteria plus a structuraland/or functional heart anomaly according to echocar-
diography, following the diagnostic criteria for HF pro-
posed by the European Society of Cardiology [23].
The basal FABP4 levels were compared to those of an
age-, gender-, and BMI-matched group of 163 non-HF
patients attending our cardiovascular risk unit for risk
factor management.
The investigation conformed to the principles outlined
in the Declaration of Helsinki. Written informed consent
was obtained from each included subject, following
the protocol approved by the Ethics Committee of
our hospitals.
During the first visit, the HF patients underwent a
complete physical examination that included a careful
evaluation of signs and symptoms of congestive HF, a
complete assessment of heart function (see below) and
the collection of relevant clinical and demographic infor-
mation. Blood samples were also collected.
A chest x-ray and electrocardiogram were performed
for each patient at the same visit. All of the patients un-
derwent a 2-dimensional Doppler echocardiography exa-
mination (GE Vivid-7, GE Healthcare, Horten, Norway).
The systolic function was quantified by measuring the
left ventricular ejection fraction using the Simpson me-
thod, according to the American Society of Echocardiog-
raphy recommendations [24].
The functional status of each patient was assessed
using the New York Heart Association classification
[25], and the 6-minute walk test (6MWT) was perfor-
med according to the standard protocol with the pa-
tients in a clinically stable condition that allowed for
ambulation without assistance [26]. At baseline, the level
of self-care behavior was evaluated using the extensively
tested and validated Minnesota Living with Heart Failure
Questionnaire (MLHFQ) [26,27]. Similar studies were
performed after a 6-month follow-up period.
Blood tests for the lipid profile, glucose, HbA1c, and
creatinine measurements were performed at baseline
and at the 6-month follow-up using standard techniques.
The NT-proBNP and FABP4 levels were determined
using commercial EIA and ELISA kits (Biomedica,
Vienna, Austria and Bio Vendor Laboratory Medicine
Inc., Brno, Czech Republic), respectively. The esti-
mated glomerular filtration rate (eGFR) was calculated
using the modification of diet in the renal disease
equation [28].
SPSS version 17.0 (SPSS Inc., Chicago, IL) was used
to carry out all of the statistical analyses. The normality
distribution was assessed using the Kolmogorov-Smirnov
test. A log-transformation was performed before the ana-
lyses when the variables exhibited a skewed distribution.
The baseline data are presented as the mean±SD or the
median with interquartile range, as appropriate, for the
continuous variables and as frequencies for the categorical






Age (years)† 70 (58–76) 68 (57–75) 0.479
Gender (M/F) 132/47 123/40 0.716
Diabetes (%) 35 51 0.002
Hypertension (%) 57 71 0.010
Obesity (%) 41 44 0.807
Waist circumference (cm) 101.8±12.9 102.9±9.8 0.315
BMI (kg/m2) 29.0 (26.5−33.1) 29.3 (27.3−31.8) 0.975
SBP (mmHg)† 120 (110–140) 137 (130–149) < 0.001
DBP (mmHg)† 70 (66–80) 85 (78–90) < 0.001
Glucose (mmol/L)† 5.9 (5.2–7.3) 6.2 (5.4–7.9) 0.386
Total-cholesterol (mmol/L) 4.72±1.29 5.03±1.11 0.028
LDL-cholesterol (mmol/L) 2.94±1.00 3.09±0.88 0.222
HDL-cholesterol (mmol/L) 1.11 (0.95–1.31) 1.34 (1.16–1.55) < 0.001
Triglycerides (mmol/L)† 1.35 (0.98–1.71) 1.50 (0.98–2.32) 0.008
FABP4 (μg/L)† 29.1 (19.2−55.0) 24.2 (19.3−34.5) < 0.001
Abbreviations: HF, heart failure; BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; LDL, Low-Density Lipoprotein; HDL,
High-Density Lipoprotein; FABP4, adipocyte fatty acid binding protein.
The data are presented as the mean±SD or median (interquartile range),
unless otherwise indicated.
*ANOVA and x2 tests were used to compare the mean of quantitative variables
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was used to compare between groups. The χ2 test was
used to compare the categorical variables between groups.
Spearman correlation tests were used to analyze the bi-
variate associations between the changes in FABP4 and
the changes in other variables. For further correlation
studies that excluded the effect of the mentioned
confounding variables on each bivariate association, the
following adjustments were made: FABP4 and NT-
proBNP levels were adjusted for age, gender, BMI, and
eGFR; triglycerides and the 6MWT results were adjusted
for the eGFR; left ventricular end-diastolic diameter and
left ventricular end-systolic diameter were both adjusted
for gender; and left ventricular ejection fraction was ad-
justed for BMI. Statistical comparisons between the cor-
relation coefficients were performed using a Fisher r to Z
testing program. The observed differences of FABP4 and
NT-proBNP before and after the follow-up period were
analyzed using the paired t-test. Changes in the variables
were calculated as the 6-month follow-up values minus
the baseline values. Partial bivariate correlation tests were
used to adjust the bivariate associations of changes in
FABP4 and NT-proBNP for the confounding variables. In
all of the cases, two-sided p<0.05 values were considered
significant.or the frequency of qualitative traits between HF and non-HF groups
of subjects.
†Log-transformed before analysis.Results
Table 1 shows the baseline characteristics of the subjects
and a comparison of the clinical and the biochemical pa-
rameters between the HF and non-HF subjects. The car-
diac functional parameters and medication histories of
the HF group are shown in Table 2. Tables 3 and 4 pre-
sents the correlation between FABP4 and NT-proBNP,
the other heart function tests and the metabolic charac-
teristics of the HF patients.FABP4 correlates with NT-proBNP
The FABP4 levels were positively correlated with the
NT-proBNP levels (r=0.291, p<0.001). After making ad-
justments for age, gender, BMI, and the eGFR, the cor-
relation became stronger (r=0.601, p<0.001) Table 3 and
Additional file 1: Figure S1A). Considering the strong
positive correlation between FABP4 and NT-proBNP,
even after excluding the effects of the confounding vari-
ables, the relationship between FABP4 and NT-proBNP
was further examined. The correlation between FABP4
and NT-proBNP was higher (p=0.05) in the HF diabetic
subjects (r=0.689, p<0.001; Additional file 1: Figure S1B)
compared to the non-diabetic HF subjects (r=0.470,
p<0.001), and the difference was even more signifi-
cant (p<0.001) in the non-obese HF subjects (r=0.883,
p<0.001; Additional file 1: Figure S1C) compared to
the obese HF subjects (r=0.605, p<0.001).FABP4 decrease during follow-up correlates with a
NT-proBNP decrease
FABP4 and NT-proBNP were re-evaluated after 6
months of follow-up, at a time when clinical improve-
ments in HF were observed. FABP4 and NT-proBNP
plasma concentration reductions occurred in parallel
during the follow-up [from 28.0 μg/L (17.4–48.7) to 23.9
μg/L (15.1–39.4) for FABP4, p<0.001, and from 641.8
pmol/L (385.4–1073.7) to 540.2 pmol/L (321.4–774.7)
for NT-proBNP, p<0.001] (Figure 1). The decreases in
FABP4 were positively correlated with decreases in NT-
proBNP (r=0.307, p=0.002) and remained significant
after adjusting for age, gender, the eGFR, and BMI at
baseline (r=0.306, p=0.005).
Basal FABP4 is higher in HF than in non-HF patients
The subjects with HF had higher FABP4 levels compared
to those without HF [29.1 μg/L (19.2–55.0) versus 24.2
μg/L (19.3–34.5), p<0.001], despite the fact that there
were more subjects with diabetes and atherogenic dys-
lipidemia in the non-HF group Table 1. The difference
between FABP4 levels in the HF and non-HF groups
remained significant even after the adjusting for age,
gender, BMI, and the presence of diabetes and athero-
genic dyslipidemia (p<0.001). As shown in Figure 2, the
Table 3 Correlations of FABP4 with metabolic factors in
the HF group
Unadjusted Adjusted for age, gender,
BMI and the eGFR
Variables r p r p
Age 0.256 0.001 0.064 0.436
Weight 0.198 0.008 0.583 < 0.001
Waist circumference 0.409 < 0.001 0.663 < 0.001
BMI 0.332 < 0.001 0.771 < 0.001
SBP 0.001 0.994 0.205 0.013
DBP 0.035 0.648 0.156 0.061
Glucose 0.053 0.529 0.205 0.018
HbA1c 0.197 0.046 0.198 0.052
Total-cholesterol −0.088 0.291 −0.013 0.884
LDL-cholesterol −0.141 0.103 −0.045 0.613
HDL-cholesterol −0.049 0.571 −0.053 0.552
Triglyceride 0.097 0.265 0.601 < 0.001
Creatinine 0.494 < 0.001 0.600 < 0.001
eGFR −0.570 < 0.001 −0.601 < 0.001
Abbreviations: BMI, body mass index; SBP: systolic blood pressure; DBP,
diastolic blood pressure; HbA1c, glycated hemoglobin, LDL, Low-Density
Lipoprotein; HDL, High-Density Lipoprotein; eGFR, estimated glomerular
filtration rate.




Heart rate (bpm) 76.2±13.6
QRS complex (ms) 120 (98–160)
QTc interval (ms) 449.0 (414.0–478.5)
PR interval (ms) 172.9±29.2
Normal sinus ECG rhythm (%) 68





Left ventricular ejection fraction (%) 32 (25–39)
NT-proBNP (pmol/L) 679.8 (405.5–1177.9)




Abbreviations: HF, heart failure; ECG, electrocardiogram; 6MWT, six-minute
walk test; MLHFQ, Minnesota Living with Heart Failure Questionnaire; LVEDD,
left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic
diameter; AI, aortic insufficiency; NT-proBNP, N-terminal fragment of pro-B
-type natriuretic peptide; ACE, angiotensin-converting enzyme.
The data are presented as the mean±SD or median (interquartile range),
unless otherwise indicated.
Table 4 Correlations of FABP4 with cardiac factors in the
HF group
Unadjusted Adjusted for age, gender,
BMI and the eGFR
Variables r p r p
Pulse pressure 0.025 0.833 0.261 0.034
Heart rate 0.190 0.013 0.150 0.075
6MWT −0.364 < 0.001 −0.610 < 0.001
MLHFQ 0.194 0.016 0.123 0.163
LVEDD −0.114 0.175 −0.023 0.796
LVESD −0.010 0.915 −0.011 0.915
AI 0.112 0.254 0.153 0.135
Left ventricular
ejection fraction
0.109 0.166 0.043 0.615
NT-proBNP 0.291 < 0.001 0.601 < 0.001
Abbreviations: 6MWT, six-minute walk test; MLHFQ, Minnesota Living with
Heart Failure Questionnaire; LVEDD, left ventricular end-diastolic diameter;
LVESD, left ventricular end-systolic diameter; AI, aortic insufficiency; NT-proBNP,
N-terminal fragment of pro-B-type natriuretic peptide.
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men, for both HF subjects [43.6 μg/L (25.2–91.8) versus
27.6 μg/L (17.3–47.7), respectively, p=0.001] and non-
HF subjects [31.6 μg/L (23.1–41.6) versus 22.5 μg/L
(16.2–32.2), respectively, p<0.001].
FABP4 is associated with a clinical assessment of HF
Table 3 presents the relationships between FABP4 and
cardiac factors. The FABP4 levels showed significant po-









































Figure 1 The serum FABP4 (white squares) and NT-proBNP
(black squares) concentrations in HF patients at baseline and













Figure 2 Comparison of the serum FABP4 levels in non-HF and
HF patients, according to gender. Black circles represent the men,
and white circles represent the women.







































































Figure 3 FABP4 and NT-proBNP relationship with functional
status and self-care behavior of HF patients. The serum FABP4
(white bars) and NT-proBNP (black bars) concentrations in HF
patients, stratified by tertiles of the 6MWT results (A) and tertiles of
the MLHFQ results (B).
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gative correlation with the 6MWT results (r=−0.364,
p<0.001) Table 4. After adjusting for age, gender, BMI,
and the eGFR, the FABP4 levels remained significantly
associated with the 6MWT results (r=−0.610, p<0.001).
Neither FABP4 nor NT-proBNP showed an association
with the ejection fraction, as estimated by the Simpson
method (r=0.043, p=0.615 and r=−0.092, p=0.330;
respectively).
We further performed a series of analyses to evaluate
the association of the FABP4 plasma levels with both the
6MWT results and the MLHFQ results, compared to the
NT-proBNP levels. In both comparisons, FABP4 showed a
similar tendency to that of NT-proBNP (Figure 3). When
all of the HF subjects were divided into 3 groups
according to the tertiles of 6MWT results, the FABP4
levels were higher in the HF subjects who presented lower
results in the 6MWT results. Considering all of the
groups, there was a negative association between FABP4
and the tertiles of 6MWT results [42.2 μg/L (25.9–81.9)
versus 26.6 μg/L (15.7–45.9) versus 24.4 μg/L (16.8–35.1),
respectively, p<0.001] (Figure 3A). Making an adjustment
for the covariates did not significantly change the asso-
ciation. Moreover, the FABP4 levels were higher in the
group with the highest MLHFQ results, and the overall
tendency was toward an increase in FABP4 levels across
the tertiles of MLHFQ results [27.9 μg/L (20.3–37.4) ver-
sus 24.0 μg/L (16.8–42.4) versus 43.0 μg/L (19.9–75.5), re-
spectively, p=0.018] (Figure 3B). However, in this case,making an adjustment for the covariates appreciably
changed the significance of the association.
These results suggested that the FABP4 levels were
higher in the subjects with a poor quality of life, esti-
mated by both the 6MWT results and the MLHFQ
results, and that the FABP4 levels showed a similar pat-
tern to that observed for the NT-proBNP levels.
FABP4 is associated with obesity and diabetes in HF
patients
In the HF subjects, the FABP4 levels were positively
associated with age, weight, waist circumference, BMI,
HbA1c, and serum creatinine levels (all p<0.01), as well
as inversely associated with the eGFR (p<0.001). After
adjusting for age, gender, BMI, and the eGFR, the FABP4
levels showed positive correlations with the systolic
blood pressure, glucose, and triglycerides (all p<0.05),
and the relationship between FABP4 and the anthro-
pometry parameters become stronger (r=0.583, p<0.001
versus r=0.198, p=0.008 for weight, and r=0.663 p<0.001
versus r=0.409, p<0.001 for waist circumference) Table 3.
The obese HF subjects had higher FABP4 levels compared
to the non-obese HF subjects [35.3 μg/L (22.3–62.3) ver-
sus 25.0 μg/L (16.6–42.5), respectively, p=0.004], even
after adjusting for age, gender, and the eGFR (p<0.001).
The HF subjects with diabetes showed higher FABP4
levels compared to the non-diabetic HF subjects [33.0 μg/L
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p=0.019], even after adjusting for age, gender, BMI and the
eGFR (p=0.002).
Discussion
Based on data from basic experiments indicating that
in vitro FABP4 induces a decrease in the contraction
capacity of myocardial cells [22], we addressed the hy-
pothesis that FABP4 is associated with HF. To test the
hypothesis, we chose the NT-proBNP sera concentrations
as our objective marker of HF. Our results demonstrate a
strong relationship between FABP4 and the HF state, as
evidenced by the NT-proBNP values. In other words,
FABP4 was directly correlated with NT-proBNP in the HF
patients. A recent study reported that FABP4 was directly
associated with NT-proBNP in Asian coronary artery
disease patients [29], and during the review process of this
study, the same group showed similar results to ours in HF
patients [30]. Moreover, Djoussé et al. reported that the
baseline FABP4 levels were associated with the risk of HF
in a prospective study but not with HF with or without left
ventricular systolic dysfunction [31]. These results are
similar to ours (no correlation between FABP4 and the
ejection fraction was observed), suggesting that circum-
stances other than myocardial function determine the
association between FABP4 and HF markers. NT-proBNP
is a useful biomarker to diagnose and manage HF. It is a
helpful tool to establish a HF diagnosis in emergency
departments, and the plasma concentration of this mol-
ecule is a marker of HF functional status. NT-proBNP has
also been proposed as an indicator for follow-up therapy
and prognosis [32,33]. The production of NT-proBNP is
stimulated by heart volume overload secondary to systolic
dysfunction. Therefore, our results, which demonstrate a
parallel association between FABP4 and NT-proBNP,
support the role of FABP4 as a HF biomarker. Addition-
ally, FABP4 was correlated to other HF clinical markers,
mainly heart rate, the 6MWT results, and MLHFQ
results, although associations with the left ventricular
ejection fraction and telediastolic volume were not
observed. The FABP4 levels showed a paralleled asso-
ciation with the NT-proBNP levels during treatment and
follow-up, suggesting that an improvement in the HF
status was associated with a reduction in both NT-
proBNP and FABP4 concentrations, although the under-
lining mechanism remains unclear. A decrease of more
than 30% in the NT-proBNP levels has been associated
with a better prognosis for HF [34]. In our follow-up
study, the HF patients who showed greater than 30%
reductions in the NT-proBNP levels also showed higher
decreases in the FABP4 levels. Although a direct
effect of treatment cannot be excluded, the drugs
affecting the FABP4 levels seem to be restricted to
statins and those influencing PPARγ activation, noneof which are the main therapeutic interventions for
HF treatment. This parallelism between a decrease in
NT-proBNP, HF clinical improvement, and a decrease
in FABP4 suggests a secondary role of FABP4
concentrations in HF. Therefore, FABP4 may be con-
sidered to be a biomarker rather than an etiological
agent. The FABP4 levels were higher in the HF patients
than in the non-HF group, despite the increased
number of subjects who were diabetic and hyperlipid-
emic in the control group, conditions associated with
higher FABP4 concentrations. This observation suggests
that HF itself could determine elevations in FABP4 con-
centrations by currently unknown mechanisms.
The strong association between NT-proBNP and
FABP4 was even higher when only the diabetic pa-
tients were considered. Because type-2 diabetes is as-
sociated with high FABP4 values, a possible link
between type-2 diabetes and an increased risk of
developing HF cannot be completely excluded. Surpris-
ingly, when obese and non-obese patients were inde-
pendently analyzed, the association between FABP4 and
NT-proBNP was higher in the non-obese group. This
association between obesity and HF is paradoxical. It
has been reported that obese patients have a reduced
risk for HF, and the overall prognosis of HF in obese pa-
tients is better. In a recent study, it was observed that
non-obese type-2 diabetic patients had a worse progno-
sis when diagnosed with HF [5]. Our results support this
observation.
A strong association between NT-proBNP and FABP4
with the creatinine levels and the eGFR was also
detected. The worse the renal function, the higher the
biomarker concentrations. We have previously repor-
ted that FABP4 concentrations are modified by renal
function, which is of special interest in diabetic pa-
tients [35]. We could consider that renal function im-
pairment is associated with HF, which would then
affect the FABP4 levels; however, when these concen-
trations were adjusted to take the renal function parame-
ters into account, the associations remained significant.
Therefore, although we cannot exclude an impact of
renal function on the FABP4 levels and on its asso-
ciation with NT-proBNP in HF patients; our data
suggest that this association was independent of renal
impairment.
Our work has several limiting factors. The first is the
relatively small sample size; however, the strength of the
results remains valuable. Second, this is an observational
study; therefore, no causal links between FABP4 and HF
can be extrapolated.
Conclusion
The FABP4 circulating levels are strongly associated and
exhibit a parallel evolution to the NT-proBNP values in
Cabré et al. Cardiovascular Diabetology 2013, 12:72 Page 7 of 8
http://www.cardiab.com/content/12/1/72HF patients. The exact mechanism underlying this asso-
ciation is not known. FABP4 could be considered to be a
new biomarker for HF, particularly in the context of
metabolic disturbances.
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Additional file 1: Figure S1. Association of serum FABP4 levels with
NT-proBNP in all HF patients studied (A), in HF patients with type 2
diabetes (B) and in non-obese HF patients (C).
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